Hanmi Announces Merger While Possible Power Struggle Surfaces

OCI Alliance Good For Future Cash Flow?

An unexpected merger between Korea's Hanmi Pharm Group and chemical group OCI may raise eyebrows in terms of likely synergies, but analysts are viewing the planned transaction positively in terms of future cash flow. However, resistance from some members of Hanmi's founder family may mean a possible leadership struggle at the pharma company.

M&A
Merger Approved Unanimously At Hanmi Science, OCI Holdings Boards • Source: Shutterstock

Hanmi Pharm Group has announced a surprise merger with OCI Group in a deal that would place the leading South Korean pharmaceutical group under the wing of the large compatriot energy and chemical enterprise.

Hanmi expects the move to help secure the investment it needs to grow into a truly global biopharma operation. “Hanmi...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

More from Focus On Asia

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By 

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut